Φορτώνει......
Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
BACKGROUND: PARP inhibitors, such as Olaparib, have advanced the treatment of ovarian cancer by providing patients with an effective and molecularly-targeted maintenance therapy. However, all orally-administered drugs, including Olaparib, must undergo first-pass metabolism. In contrast, a nanopartic...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Int J Nanomedicine |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6278886/ https://ncbi.nlm.nih.gov/pubmed/30555227 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S186881 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|